The insulin-independent hypoglycemic mechanism indicates that theoretically, SGLT2 inhibitors might be effective in patients with any stage of diabetes and particularly effective in those with severe insulin resistance and receiving high-dosage insulin therapy. This evidence concerns the gene INS and diabetes mellitus.